Matches in Wikidata for { <http://www.wikidata.org/entity/Q33432958> ?p ?o ?g. }
- Q33432958 description "2016 nî lūn-bûn" @default.
- Q33432958 description "2016 թուականի Յունիսին հրատարակուած գիտական յօդուած" @default.
- Q33432958 description "2016 թվականի հունիսին հրատարակված գիտական հոդված" @default.
- Q33432958 description "2016年の論文" @default.
- Q33432958 description "2016年論文" @default.
- Q33432958 description "2016年論文" @default.
- Q33432958 description "2016年論文" @default.
- Q33432958 description "2016年論文" @default.
- Q33432958 description "2016年論文" @default.
- Q33432958 description "2016年论文" @default.
- Q33432958 description "2016年论文" @default.
- Q33432958 description "2016年论文" @default.
- Q33432958 description "2016年论文" @default.
- Q33432958 description "2016年论文" @default.
- Q33432958 description "2016年论文" @default.
- Q33432958 description "2016년 논문" @default.
- Q33432958 description "article científic" @default.
- Q33432958 description "article scientific" @default.
- Q33432958 description "article scientifique (publié 2016)" @default.
- Q33432958 description "articol științific" @default.
- Q33432958 description "articolo scientifico" @default.
- Q33432958 description "artigo científico (publicado na 2016)" @default.
- Q33432958 description "artigo científico (publicado na 2016)" @default.
- Q33432958 description "artigo científico" @default.
- Q33432958 description "artikull shkencor" @default.
- Q33432958 description "artikulong pang-agham" @default.
- Q33432958 description "artykuł naukowy" @default.
- Q33432958 description "artículo científico publicado en 2016" @default.
- Q33432958 description "artículu científicu espublizáu en 2016" @default.
- Q33432958 description "bilimsel makale" @default.
- Q33432958 description "bài báo khoa học" @default.
- Q33432958 description "mokslinis straipsnis" @default.
- Q33432958 description "naučni članak" @default.
- Q33432958 description "scienca artikolo" @default.
- Q33432958 description "scientific article" @default.
- Q33432958 description "teaduslik artikkel" @default.
- Q33432958 description "tieteellinen artikkeli" @default.
- Q33432958 description "tudományos cikk" @default.
- Q33432958 description "vedecký článok" @default.
- Q33432958 description "vetenskaplig artikel" @default.
- Q33432958 description "videnskabelig artikel (udgivet 2016)" @default.
- Q33432958 description "vitenskapelig artikkel" @default.
- Q33432958 description "vitskapeleg artikkel" @default.
- Q33432958 description "vědecký článek" @default.
- Q33432958 description "wetenschappelijk artikel" @default.
- Q33432958 description "wissenschaftlicher Artikel" @default.
- Q33432958 description "επιστημονικό άρθρο" @default.
- Q33432958 description "мақолаи илмӣ" @default.
- Q33432958 description "мақолаи илмӣ" @default.
- Q33432958 description "наукова стаття, опублікована в червні 2016" @default.
- Q33432958 description "научна статия" @default.
- Q33432958 description "научная статья" @default.
- Q33432958 description "научни чланак" @default.
- Q33432958 description "научни чланак" @default.
- Q33432958 description "מאמר מדעי" @default.
- Q33432958 description "سائنسی مضمون" @default.
- Q33432958 description "مقالة علمية" @default.
- Q33432958 description "مقالهٔ علمی" @default.
- Q33432958 description "২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q33432958 description "บทความทางวิทยาศาสตร์" @default.
- Q33432958 description "სამეცნიერო სტატია" @default.
- Q33432958 name "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 name "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 name "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 type Item @default.
- Q33432958 label "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 label "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 label "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 prefLabel "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 prefLabel "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 prefLabel "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma." @default.
- Q33432958 P1433 Q33432958-1E98C1E0-9AE5-4B9A-A48D-67BFB6D8776D @default.
- Q33432958 P1476 Q33432958-48F57D7F-32DA-4E18-B78D-9CD591E49F14 @default.
- Q33432958 P2093 Q33432958-00EF2DB4-A0BD-4CBE-8D5A-2B916F092405 @default.
- Q33432958 P2093 Q33432958-0DBFDDD6-0ED1-48F4-8543-9AC3D7173A69 @default.
- Q33432958 P2093 Q33432958-2CAEDE45-73ED-401B-A8E3-CEBDD0CB5BB6 @default.
- Q33432958 P2093 Q33432958-715E19E5-91A8-415A-A046-1F862D650FCB @default.
- Q33432958 P2093 Q33432958-7F7AEF13-54D1-428D-B2E5-7311CAAEED78 @default.
- Q33432958 P2093 Q33432958-8DBF7843-985C-4C22-9058-5DAA57C3BE3C @default.
- Q33432958 P2093 Q33432958-A7C54521-36D3-48D4-9DB1-CED7276C1EDB @default.
- Q33432958 P2093 Q33432958-AB401D1F-E758-4924-ADC8-BB457FD9AE3C @default.
- Q33432958 P2093 Q33432958-B401F17F-748E-49E4-9DF2-DC7C7C9CC365 @default.
- Q33432958 P2093 Q33432958-BA82BE03-3433-405A-B8BD-DC54542DECB0 @default.
- Q33432958 P2093 Q33432958-C1BF99AB-40AF-4349-BEDE-06965ED9724C @default.
- Q33432958 P2093 Q33432958-C4E9A127-8031-40B4-AAFE-9AB167D960A1 @default.
- Q33432958 P2093 Q33432958-F8ACD9CA-37DF-4415-B48B-86A892BBE164 @default.
- Q33432958 P304 Q33432958-897D4C8D-4D08-42AF-A8FB-4541470ED99D @default.
- Q33432958 P31 Q33432958-487BEEB5-0D7F-4C11-822B-4254D03E81DD @default.
- Q33432958 P356 Q33432958-49618E41-BFC2-4A5D-BCB8-9BF9EDC53F4F @default.
- Q33432958 P407 Q33432958-6D9CFE06-0FA8-41DC-A829-1C40535B52E4 @default.
- Q33432958 P433 Q33432958-05DC5201-AAD8-4ED7-B4A2-9CD6F822A9C2 @default.
- Q33432958 P478 Q33432958-274CF871-FC9D-4A98-A8ED-044D5C1F9906 @default.
- Q33432958 P50 Q33432958-9E535976-5977-4411-9A87-B3CC0FE23B55 @default.
- Q33432958 P577 Q33432958-C110DAD5-D6D8-491C-AD06-A8B65F180101 @default.
- Q33432958 P698 Q33432958-5B696793-6458-442D-BF5D-2862958A0568 @default.
- Q33432958 P356 1078-0432.CCR-16-0201 @default.
- Q33432958 P698 27287072 @default.
- Q33432958 P1433 Q332253 @default.
- Q33432958 P1476 "Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma" @default.
- Q33432958 P2093 "Andres Forero" @default.